Medivir appoints John Öhd as Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that John Öhd, MD, PhD has been appointed as its new Chief Medical Officer.

“I am pleased to appoint John Öhd, currently clinical R&D head, to the newly created position of Chief Medical Officer, reporting to me” says CEO, Christine Lind. “With the broad clinical pipeline that Medivir has, it is important for us to have an executive leader in this position. John’s unique and broad experiences as a drug developer, clinician and experimental scientist make him an exceptional choice for this role on Medivir’s Executive Leadership Team.”

John Öhd has been Medivir’s Director, Clinical Research & Development since 2014, prior to which he was senior director of Experimental Medicine at Shire in Nyon, Switzerland. John has held various positions at AstraZeneca in Södertälje, Sweden, including group director for early development in cognitive and neurodegenerative disorders. He worked in cancer research initially at Lund University where he received a PhD in Experimental Pathology and subsequently at Karolinska Institute. John received his MD from Linköping University, and trained clinically at Karolinska University Hospital.

   
For further information, please contact :
Ola Burmark, CFO Medivir AB, mobil: +46 (0)725-480 580.

   
About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Tags:

About Us

Medivir is an emerging and profitable research‐based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals.Medivir receives royalties from Johnson & Johnson on the global sales of the hepatitis C pharmaceutical, Olysio®. In addition, revenues for sales of Olysio in the Nordic region are generated through the company’s own sales and marketing organisation. Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science. The company’s research and development focus is within infectious diseases and oncology and the on-going clinical projects in osteoarthritis and neuropathic pain. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Subscribe

Documents & Links